BMS eyes another celmod filing in myeloma after phase 3 win
Bristol Myers Squibb now has positive phase 3 data under its belt for celmod mezigdomide, as it waits for an FDA verdict on lead drug iberdomide.
Novo partners with Hims & Hers again, ending GLP-1 spat
Novo Nordisk and Hims & Hers have set their differences aside, agreeing to work together once again on the sale of GLP-1 agonists.
Incyte breaks new ground in anal cancer with EU approval
Incyte claims EU approval for Zynyz as the first systemic therapy for anal cancer, as J&J gets the nod for wider use of Akeega in prostate cancer.
Alfasigma licenses liver drug from GSK in $690m deal
With an FDA verdict looming, GSK has signed an eleventh-hour deal to give Alfasigma rights to its primary biliary cholangitis therapy linerixibat.
Roche's oral SERD flunks phase 3 breast cancer test
Roche's recent run of positive study results with breast cancer candidate giredestrant has come to an end with the failure of the persevERA trial.
Sales & Marketing
Digital
Market Access
Oncology
Patients
R&D
Partner Content
PHARMAP 2026: Where Pharma Meets Policy
The Pharmaceutical Manufacturing and Packaging Congress (PHARMAP 2026)
7th Dermatology Drug Development Summit Europe
The Summit is a premier three-day industry event designed for senior leaders, clinical scientists, regulatory experts and commercial strategists
The PM Society Launches Pharmony to Support More Effective P...
The Pharmaceutical Marketing Society (PM Society) today announces the launch of Pharmony
EVERSANA Names Monica Avram Executive Vice President and Chi...
As chief legal officer and a member of the Executive Leadership Team, Monica Avram leads EVERSANA's global Legal and Compliance function.
Emerging Trends in Personalised Medicine at PHARMAP 2026
The Pharmaceutical Manufacturing & Packaging Congress is an exclusive annual event that fosters networking and knowledge-sharing among professionals